Serological Response of Non-human Primates to Human Melanoma Disialoganglioside GD3

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1989 Jan 1

PMID 2731185

Authors

G M Stuhlmiller

K M Roberson

H F Seigler

Affiliations

Soon will be listed here.

Abstract

The immunogenicity of the disialoganglioside, GD3, a melanoma-tumor-associated antigen, has been evaluated in non-human primates. Sera from four chimpanzees and two monkeys were evaluated for anti-GD3 antibody activity by solid-phase radioimmunoassay using GD3 and control gangliosides as targets. Serum from one monkey, immunized with cells from a melanoma cell line, was strongly reactive with GD3, having a titer of greater than 2500. In contrast, serum from this animal was non-reactive with several other gangliosides including the structurally similar GM3. Anti-GD3 reactivity was also demonstrable, albeit in low titer, in the sera of an additional monkey and a chimpanzee. Each of these animals had likewise been immunized using cells from melanoma cell lines. On the basis of these observations, suggestive of a primate anti-GD3 antibody response, we initiated a series of immunizations of chimpanzee using purified GD3 bound to Salmonella minnesota, R595. IgG reactive with melanoma cells in the cell-binding assay was first detected in sera collected after 4 immunizations and increased in titer against each reactive melanoma cell line during the immunizations. Reactivity of this serum with melanoma cell lines demonstrated a direct correlation with the expression of GD3 by the respective cell line. Anti-GD3 reactivity was evident in solid-phase radioimmunoassay against purified GD3 beginning with serum collected after 11 immunizations. By comparison with its binding to the control ganglioside panel, this serum demonstrated strong specificity for GD3 (titer = 640) while having only marginal reactivity with GM3 (titer = 40). Immune serum from this animal was also able specifically to block subsequent binding of a murine IgM anti-GD3 antibody (DMab7) to target GD3 in solid-phase radioimmunoassay. Together, these observations suggest that GD3, in the form of a purified molecule bound to a bacterial matrix or as part of the intact melanoma cell membrane, can be immunogenic in non-human primates, and is able to elicit an antibody response of appropriate specificity.

References

Hersey P . Review of melanoma antigens recognized by monoclonal antibodies (MAbs). Their functional significance and applications in diagnosis and treatment of melanoma. Pathology. 1985; 17(2):346-54. DOI: 10.3109/00313028509063778. View

Seigler H, METZGAR R, Mohanakumar T, Stuhlmiller G . Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. Fed Proc. 1975; 34(8):1642-6. View

Honsik C, Jung G, Reisfeld R . Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A. 1986; 83(20):7893-7. PMC: 386829. DOI: 10.1073/pnas.83.20.7893. View

Singer K, Hashimoto K, Stuhlmiller G, Lazarus G . Antibody-induced release of cellular proteinases: loss of adhesion of human melanoma cells after binding of anti-melanoma antibody. J Immunol. 1982; 128(3):1321-6. View

Seigler H, Cox E, Mutzner F, Shepherd L, Nicholson E, SHINGLETON W . Specific active immunotherapy for melanoma. Ann Surg. 1979; 190(3):366-72. PMC: 1344672. DOI: 10.1097/00000658-197909000-00012. View

Real F, Houghton A, Albino A, Cordon-Cardo C, Melamed M, Oettgen H . Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 1985; 45(9):4401-11. View

Stuhlmiller G, Mohanakumar T, METZGAR R, Seigler H . The use of non-human primates for production of antisera to human tumor-associated antigens. J Immunol Methods. 1976; 12(3-4):267-74. DOI: 10.1016/0022-1759(76)90048-x. View

Dippold W, Knuth A, Meyer zum Buschenfelde K . Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 1984; 44(2):806-10. View

Mutzner P, Stuhlmiller G, Seigler H . Characterization of melanoma cell membrane tumor-associated antigens using xenoserum, alloserum, and autoserum: I. immunofluorescence. J Surg Oncol. 1980; 14(4):367-77. DOI: 10.1002/jso.2930140411. View

10.

Cheresh D, Honsik C, Staffileno L, Jung G, Reisfeld R . Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci U S A. 1985; 82(15):5155-9. PMC: 390518. DOI: 10.1073/pnas.82.15.5155. View

11.

Stuhlmiller G, Borowitz M, Seigler H . D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. Hybridoma. 1984; 3(4):333-46. DOI: 10.1089/hyb.1984.3.333. View

12.

Svennerholm L, Fredman P . A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta. 1980; 617(1):97-109. DOI: 10.1016/0005-2760(80)90227-1. View

13.

Stuhlmiller G, Seigler H . Characterization of a chimpanzee anti-human melanoma antiserum. Cancer Res. 1975; 35(8):2132-7. View

14.

Seigler H, Wallack M, Vervaert C, Bash J, Roberson K, Stuhlmiller G . Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. J Biol Response Mod. 1989; 8(1):37-52. View

15.

Galanos C, LUDERITZ O, Westphal O . Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem. 1971; 24(1):116-22. DOI: 10.1111/j.1432-1033.1971.tb19661.x. View

16.

Dippold W, LLOYD K, Li L, Ikeda H, Oettgen H, Old L . Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980; 77(10):6114-8. PMC: 350224. DOI: 10.1073/pnas.77.10.6114. View

17.

Wikstrand C, Bigner D . Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies. Cancer Res. 1982; 42(1):267-75. View

18.

Houghton A, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S . Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985; 82(4):1242-6. PMC: 397231. DOI: 10.1073/pnas.82.4.1242. View

19.

Stuhlmiller G, Darrow T, Haupt D, Seigler H . Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. Cancer Immunol Immunother. 1987; 25(3):193-200. PMC: 11038389. DOI: 10.1007/BF00199147. View

20.

Hunter W, GREENWOOD F . Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962; 194:495-6. DOI: 10.1038/194495a0. View